EANS-Adhoc: Sartorius AG / Sales revenue and earnings for the Biotechnology Division further increased | Significantly improved order situation and positive earnings for the Mechatronics Division

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Figures for the First Three Months of 2010

20.04.2010

In the first three months, the Sartorius Group received orders valued
at EUR167.2 million (mn), up from EUR157.0 mn and thus 6.5%
(currency-adjusted: +7.6%) more than in the year-earlier quarter.
Sales revenue rose 3.0% (currency-adj.: +4.1%) to EUR150.4 mn from
EUR146.0 mn a year ago. For the Biotechnology Division, order intake
climbed 5.8% (currency-adj.: +6.7%) to EUR110.4 mn from EUR104.4 mn a
year earlier, and sales revenue grew 3.7% (currency-adj.: +4.8%) to
EUR100.1 mn from EUR96.6 mn in the prior-year quarter. The
Mechatronics Division obtained orders worth EUR56.8 mn (previous
year: EUR52.6 mn) and thus significantly boosted its order volume by
7.9% (currency-adj.: +9.2%). Sales revenue for the Mechatronics
Division edged up 1.8% (currency-adj.: +2.8%) from EUR49.5 mn to
EUR50.4 mn.

Consolidated earnings before interest, taxes and amortization and
adjusted for extraordinary expenses of EUR0.9 mn (underlying EBITA)
rose year on year from EUR10.9 mn to EUR16.4 mn; the respective
margin, from 7.5% to 10.9%. The Biotechnology Division contributed
EUR14.6 mn, up from EUR12.8 mn a year ago, and raised its margin year
on year from 13.3% to 14.6%. Compared with the previous year (-EUR1.9
mn), the Mechatronics Division swung back to profitability,
contributing positive earnings of EUR1.8 mn and increasing its margin
from -3.9% to +3.7%.

Excluding non-cash amortization, consolidated adjusted net profit
after minority interest is at EUR6.9 mn, up from EUR2.4 mn a year
ago; the respective earnings per share, at EUR0.41, up from EUR0.14.
The ratio of net debt to EBITDA is at 2.6.

The results achieved meet our expectations for both divisions and
confirm our outlook for the current fiscal year. This outlook
forecasts sales growth of slightly above 5% in constant currencies
and further improvement of the operating EBITA margin by one to two
percentage points as well as a significantly positive operating cash
flow.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius,
will discuss the results with analysts and investors on Wednesday,
April 21, 2010, at 4:30 p.m. Central European Time in a webcast
teleconference. You may dial into the telecon-ference starting at
4:15 p.m. CET at the following numbers: Germany +49 (0)69 9897 2623;
France +33 (0)1 70 99 42 85; UK +44 (0)20 7138 0843; USA +1 212 444
0895 The dial-in code is: 9427275 The webcast and presentation can be
viewed at www.sartorius.com.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Andreas Wiederhold

Team Leader Treasury & Investor Relations

Telefon: +49 (0)551 308-1668

E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

EANS-Adhoc: Sartorius AG / Sales revenue and earnings for the Biotechnology Division further increased | Significantly improved order situation and positive earnings for the Mechatronics Division | Do